-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $243

Benzinga·04/14/2026 14:56:03
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $239 to $243.